Lixa develops revolutionary, scalable solutions for antimicrobial resistance (AMR) and the US$5T per annum biofilm problem.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Lixa — Funding & Investors." VCBacked, September 6, 2022, https://www.vcbacked.co/company/lixa. Accessed July 1, 2026.
VCBacked. (2022). Lixa — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/lixa
{{cite web |title=Lixa — Funding & Investors |url=https://www.vcbacked.co/company/lixa |website=VCBacked |access-date=July 1, 2026}}Profile data sourced and verified per the VCBacked methodology. Last funding round dated .